Institution
Rappaport Faculty of Medicine
About: Rappaport Faculty of Medicine is a based out in . It is known for research contribution in the topics: Population & Heparanase. The organization has 3205 authors who have published 3915 publications receiving 114533 citations.
Topics: Population, Heparanase, Medicine, Cancer, Pregnancy
Papers published on a yearly basis
Papers
More filters
••
TL;DR: The antiatherogenic properties of fluvastatin may not be limited to its hypocholesterolemic effect, but could also be related to its ability to reduce LDL oxidizability.
172 citations
••
Ohio State University1, Memorial Sloan Kettering Cancer Center2, University of Manitoba3, Hofstra University4, Mayo Clinic5, Institute of Cancer Research6, Semmelweis University7, National Institute for Health Research8, Heidelberg University9, Lund University10, Laboratory of Molecular Biology11, University of Alberta12, University of Barcelona13, Hebrew University of Jerusalem14, University Health Network15, University of Texas MD Anderson Cancer Center16, Medical University of Łódź17, Scripps Health18, Peter MacCallum Cancer Centre19, Rappaport Faculty of Medicine20, University of Rochester Medical Center21, German Cancer Research Center22, University of Bologna23
TL;DR: The development of consensus guidelines for this disease offers a framework for continued enhancement of the outcome for patients, and organized evaluations of minimal residual disease and treatment at relapse offer ample opportunities for clinical research.
171 citations
••
TL;DR: There is a continued need for innovation and new-class antibacterial agents in order to provide effective therapeutic options against infections specifically caused by XDR and PDR Gram-negative bacteria.
Abstract: The antibacterial agents currently in clinical development are predominantly derivatives of well-established antibiotic classes and were selected to address the class-specific resistance mechanisms and determinants that were known at the time of their discovery. Many of these agents aim to target the antibiotic-resistant priority pathogens listed by the WHO, including Gram-negative bacteria in the critical priority category, such as carbapenem-resistant Acinetobacter, Pseudomonas and Enterobacterales. Although some current compounds in the pipeline have exhibited increased susceptibility rates in surveillance studies that depend on geography, pre-existing cross-resistance both within and across antibacterial classes limits the activity of many of the new agents against the most extensively drug-resistant (XDR) and pan-drug-resistant (PDR) Gram-negative pathogens. In particular, cross-resistance to unrelated classes may occur by co-selection of resistant strains, thus leading to the rapid emergence and subsequent spread of resistance. There is a continued need for innovation and new-class antibacterial agents in order to provide effective therapeutic options against infections specifically caused by XDR and PDR Gram-negative bacteria. New antibacterial agents are urgently needed to address the global increase in resistance. In this Review, Theuretzbacher and colleagues critically review the current published literature and publicly available information on antibacterial agents in all phases of clinical development.
171 citations
••
TL;DR: Optogenetics, widely used to modulate neuronal excitability, is applied for cardiac pacing and resynchronization therapies and diffuse illumination of hearts where the ChR2 transgene was delivered to several ventricular sites resulted in electrical synchronization and significant shortening of ventricular activation times.
Abstract: Abnormalities in the specialized cardiac conduction system may result in slow heart rate or mechanical dyssynchrony. Here we apply optogenetics, widely used to modulate neuronal excitability, for cardiac pacing and resynchronization. We used adeno-associated virus (AAV) 9 to express the Channelrhodopsin-2 (ChR2) transgene at one or more ventricular sites in rats. This allowed optogenetic pacing of the hearts at different beating frequencies with blue-light illumination both in vivo and in isolated perfused hearts. Optical mapping confirmed that the source of the new pacemaker activity was the site of ChR2 transgene delivery. Notably, diffuse illumination of hearts where the ChR2 transgene was delivered to several ventricular sites resulted in electrical synchronization and significant shortening of ventricular activation times. These findings highlight the unique potential of optogenetics for cardiac pacing and resynchronization therapies.
171 citations
••
TL;DR: Quantification of the total iron content in iron-loaded NM and synthetic melanin demonstrated that the iron-binding capacity of NM is 10-fold greater than that of the model melanin.
168 citations
Authors
Showing all 3205 results
Name | H-index | Papers | Citations |
---|---|---|---|
Barry M. Brenner | 121 | 540 | 65006 |
Robert R. Edelman | 119 | 605 | 49475 |
David M. Goldenberg | 108 | 1238 | 48224 |
Moussa B.H. Youdim | 107 | 574 | 42538 |
Aaron Ciechanover | 105 | 315 | 58698 |
Israel Vlodavsky | 98 | 494 | 34150 |
Basil S. Lewis | 96 | 651 | 60124 |
Michael Aviram | 94 | 479 | 31141 |
Abraham Weizman | 81 | 1011 | 31083 |
Thomas N. Robinson | 81 | 309 | 26121 |
Peretz Lavie | 81 | 320 | 21532 |
Jacob M. Rowe | 75 | 328 | 20043 |
Hossam Haick | 72 | 279 | 15646 |
Walid Saliba | 70 | 359 | 19254 |
Gad Rennert | 67 | 350 | 17349 |